MetaVia's interim Phase 1 data for DA-1726, a once-weekly oxyntomodulin analog acting on both GLP-1 and glucagon receptors, reported a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at 16 weeks in a 16-participant MRI substudy. All five treated participants with baseline steatosis fell below the 5% MRI-PDFF threshold by Day 109, while gastrointestinal adverse events occurred in nine of 15 treated participants. Hepatic fat content is a modifiable driver of metabolic deterioration, making the magnitude of reduction relevant despite the small sample.
Key Points
- 68% placebo-adjusted liver fat reduction after 16 weeks of treatment
- Dual GLP-1/glucagon agonism produced 13.5% placebo-adjusted weight loss
- Gastrointestinal events in nine of 15 treated participants, one severe
Longevity Analysis
Excess hepatic fat sits upstream of insulin resistance, dyslipidemia and chronic low-grade inflammation, and clearing it restores the liver's capacity to regulate glucose, process metabolic waste and coordinate hormonal signaling. Glucagon receptor engagement adds a direct hepatic fat oxidation mechanism that incretin agonism alone does not deliver, which may explain the separation between fat loss in the liver and overall weight change. The tolerability profile — vomiting in roughly half of treated participants — remains the limiting variable, and small single-arm substudies of this size cannot yet establish whether the hepatic benefit persists beyond the weight loss that accompanies it.
Original published by LT Wire.